Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
News Release Digital Asset Direct

10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar

Benzinga

By Faith Ashmore, Benzinga The WHO reports that colorectal cancer is the second most fatal cancer around the world. However, it is also the most preventable, with early detection leading to survival rates above 90%. Alarming statistics reveal that new cases of colorectal cancer in individuals under the age of 50 have been steadily rising over the past few decades. Colorectal cancer is now the leading cause of cancer death for Americans between the ages of 20 and 59 years old according to the National Cancer Institute. However, younger adults are not routinely screened for colorectal cancer as it is still relatively uncommon in their age group. Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The company seems to be gaining momentum in the industry, and here are 10 reasons you may want to keep your eye on them. Flagship Product For Early Detection Mainz Biomed has developed a flagship product, ColoAlert, which has the potential to establish the company as a frontrunner in the early detection of colorectal cancer. By providing a highly sensitive and accurate screening tool, ColoAlert has the capacity to revolutionize the way colorectal cancer is detected and treated. The test is the first DNA-based screening test for colorectal cancer in Europe, which sees the highest incidence rate for colorectal cancer. Tapping into A Multi-Billion Dollar Market While this innovative screening tool will be useful to young people who don’t get regular screenings, is not limited to younger ages. In fact, ColoAlert may have an annual market opportunity of around $3.7 Billion in the U.S. for testing populations aged 50 and above every three years, as recommended by the FDA. ColoAlert's unique genetic profiles allow for tailored treatment for each individual patient, leading to better health outcomes for patients with colorectal cancer. This revolutionary product is a major stride in combating colorectal cancer and has the potential to save countless lives. As GenX individuals age into their 40s and 50s, they become part of the age group recommended for colorectal cancer screening. This demographic shift presents a significant market opportunity as the demand for screening and related services continues to rise. Experienced Leadership Team Mainz Biomed has successfully attracted former executives from major pharmaceutical giants to its leadership team. CEO Guido Baechler, a former Roche Molecular Diagnostics executive, brings invaluable expertise to the company's strategic development. Additionally, Chief Commercial Officer Darin Leigh's extensive executive commercial experience across leading life science and healthcare firms further strengthens the company’s leadership. Positive Feedback And Upcoming Studies Mainz Biomed has already received encouraging feedback for its lead product, ColoAlert. This feedback serves as an endorsement of the product's effectiveness and potential impact on early detection. Furthermore, the company expects upcoming study data to validate the clinical benefits and efficacy of ColoAlert, further bolstering its role as an essential tool in colorectal cancer screening. Detecting Precancerous Conditions The company's focus on detecting advanced adenoma represents a significant stride in identifying colorectal cancer at a precancerous stage. By identifying and removing these precursors during screening, Mainz Biomed helps prevent the progression of the disease and reduces the risk of developing colorectal cancer. This early intervention can have a profound impact on patient outcomes and survival rates. Strong Price Target Analysts have set an $11 price target for MYNZ, reflecting the positive sentiment surrounding the company's growth potential. This price target implies confidence in Mainz Biomed’s ability to capture a significant share of the market and generate value for investors. The company has seen significant revenue growth in 2023 -- the revenues generated by ColoAlert in the first half of 2023 surged by 108% when compared to the same period in 2022 as the company expanded international commercialization for ColoAlert and entered new markets in Europe. This remarkable growth further solidifies Mainz Biomed's position in the industry and showcases its ability to develop groundbreaking products that meet the needs of healthcare professionals and patients alike. Flagship Product Competes With Large Players Mainz Biomed's ColoAlert competes with Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), a well-established company that commands a market cap of over $10 billion. It’s clear that even in the earlier stages, Mainz Biomed is shaping up to be a formidable player in the field of early detection for colorectal cancer. Expanding International Presence The company is actively pursuing international commercial activities to introduce ColoAlert to a global market. By expanding its reach, it aims to increase accessibility to its innovative screening product, ensuring early detection and prevention of colorectal cancer on a global scale. Strong Financial Position The company also boasts of a stable financial position due to ample cash reserves, enabling the company to fund ongoing operations and drive growth initiatives effectively. In June, the company secured up to $50 million in new funding. This financial strength provides Mainz Biomed with the stability and resources necessary to invest in research and development, expand its portfolio and bring innovative products to market. Strategic Partnership For Novel Biomarkers The company has established a strategic partnership with Microba Life Sciences to explore the discovery and integration of novel microbiome biomarkers into its pipeline asset, PancAlert. By leveraging Microba's expertise, the company aims to develop PancAlert into a potential first-in-class screening test for pancreatic cancer, addressing a critical need for early detection of this challenging disease. The Future For Mainz Biomed And Cancer Diagnostics Mainz Biomed is on a mission to become a leading global provider of easy-to-use diagnostic solutions for patients and healthcare providers everywhere. The company heads into the second half of 2023 confident of future growth as ColoAlert gains more traction in Europe and select international markets. The company also has a busy pipeline. It is ramping up enrollment planning for ReconAAsense – the company’s U.S. pivotal study for its flagship product – and executing clinical trials evaluating a portfolio of proprietary novel gene expression (mRNA) biomarkers for potential inclusion into ReconAAsense. Through its partnership with Microba Life Sciences, Mainz is also advancing PancAlert, its next-generation pancreatic cancer detection test. Interested investors may want to watch out for data from the company’s two feasibility studies. With a combination of innovative products, experienced leadership, an active pipeline and strategic collaborations, Mainz Biomed seems well-positioned to make a significant impact on the early detection of colorectal and potentially other markets like pancreatic cancers. Their commitment to pushing the boundaries of diagnostic technology and growth trajectory seems to be making them a force to be reckoned with in the industry, setting them apart from their competitors. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 06, 2023 09:25 AM Eastern Daylight Time

Octane11 Introduces the "B2B Marketing Impact Audit”

Octane11

Octane11, the B2B marketing analytics platform known for its industry-leading integration of marketing and sales data, announced today the release of its new product: the Octane11 B2B Marketing Impact Audit. The B2B Marketing Impact Audit will revolutionize the way B2B companies assess, plan, and optimize their marketing and sales tactics. "We recommend Octane11’s B2B Marketing Impact Audit for all of our clients. It’s remarkably powerful with a fast and seamless set up,” said Scott Stedman, CEO of The Imaginarium. “It offers a ‘set it and forget it’ experience that delivers a concise yet comprehensive analysis of valuable insights in just 30 days, empowering our clients to ensure that their marketing engine is driving maximum revenue growth.” As marketers continue to navigate uncertain economic times and lean budgets, the B2B Marketing Impact Audit enables B2B CMOs to enhance year-end performance and make informed investment decisions for the upcoming year. The end-to-end analysis across paid, owned, and earned marketing tools and the sales CRM, provides a holistic and in-depth view of existing marketing expenditures and performance, which is especially critical as businesses strategize to invest wisely amidst this unpredictable macroeconomic environment. Delivering Proven Value to Marketer s Fast and Easy Setup: Octane11’s team of experts guide businesses through setup in four live sessions, ensuring data quality and completeness. The Audit then runs in the background for thirty (30) days. Unified Scorecard: The Audit produces a summary scorecard featuring 20 critical KPIs including ROI, Cost-per-Lead, and % of Target Accounts Engaged; marketers also receive performance comparisons against industry peers and a clear letter grade, highlighting key areas for immediate improvement. Comprehensive Analysis: The Audit includes 15 pages of clear visualizations and expert analysis, including practical and tangible recommendations on effective budgeting, tactic optimization and growth acceleration through incremental, Octane11-certified strategies. Industry Benchmarks: Company data is benchmarked against a range of B2B peers, enabling marketers to contextualize their performance with real-world comparisons updated quarterly as market conditions and the vendor landscape evolve. Interactive Access: Clients also receive access to live dashboard views, enabling them to dive deeper into the information through drill downs and scenarios, share findings with colleagues, and export data into CRM or BI platforms. Data Health and Alignment: The Audit also identifies anomalies in data setup and flags any misalignment between the marketing and sales teams’ objectives. Data Protection: The Audit is SOC2-compliant and utilized by leading privacy-focused Fortune 500 clients. It also provides the option to omit PII at the clients’ request. For a deeper dive into the features and benefits of the B2B Marketing Stack Audit, please visit www.octane11.com/audit. About Octane11 Octane11 is a B2B-focused data analytics and collaboration platform that connects paid, owned, and earned marketing, sales, and product usage data to drive real business results. We help B2B enterprises with $100M+ in revenue to integrate, enrich, and analyze data across teams, and compare performance to industry benchmarks. Octane11 is backed by Javelin Venture Partners, BDMI, Honeystone Ventures, Circadian Ventures, Plug and Play Ventures, Base Ventures, and AperiamVentures. Launched in 2020, Octane11 is already helping some of the largest B2B enterprises break down data silos and turn every digital interaction into an actionable insight. To learn more, visit www.octane11.com and follow us on LinkedIn. For media inquiries and more information, contact: press@octane11.com Contact Details Octane11 Press Inquiries +1 646-397-1631 press@octane11.com Company Website http://www.octane11.com

September 06, 2023 09:05 AM Eastern Daylight Time

Logitix Names Live Entertainment Executive Wendi Rohan Lebow as Vice President of Open Distribution

Logitix

Logitix, a leader in live event ticketing technology and analytics, announced it has named Wendi Rohan Lebow as Vice President of Open Distribution. Lebow will oversee Logitix’s proprietary technology, Open Distribution, which allows venues and live event companies to distribute, price, and sell their primary ticket inventory across multiple integrated marketplaces that Logitix utilizes. Lebow’s extensive live entertainment experience includes leadership roles at TodayTix Group and Goldstar Events, Inc. Lebow’s role as Vice President of Open Distribution is a newly created position for Logitix, which works with venues and live event companies across the performing arts, music, and sports. As an innovative product that is changing how the industry sells and distributes tickets, Open Distribution by Logitix is a native integration with the organization’s primary ticketing system that allows designated tickets to be listed on the primary and secondary channels at the same time. The technology leverages the primary ticketing system’s native fulfillment methods, ensuring the fan gets their ticket and the venue obtains customer information seamlessly. At Logitix, Lebow will work cross-functionally with Logitix’s product, marketing, operations, and business development, in addition to collaborating with external partners to optimize the use of Open Distribution. “The demand and interest in our Open Distribution product from across the live event industry is skyrocketing daily, and the need for a top-tier executive to lead this area for us became clear,” said Logitix CEO Stu Halberg. “We are fortunate to have Wendi join our leadership team. She is a well-respected ticketing professional who has helped thousands of brands sell millions of tickets throughout her career.” “I’ve had the opportunity to partner with Wendi and her team when I was at Tessitura and she was leading venue partnerships for Goldstar,” said Logitix Strategic Advisor Jack Rubin, the Co-Founder and former CEO of Tessitura Network. “Wendi’s experience with distribution technologies, especially in the performing arts industry, is world-class. She is a tremendous addition to the Logitix team who understands the sectors served and will help the organizations create revenue. I look forward to working with her and building on the success created to date.” Lebow led venue relations and partnerships for Goldstar Events, Inc. for 15 years, rising to the position of Chief Venue Officer. Goldstar was acquired by TodayTix Group in 2021 when Lebow transitioned to the role of Vice President of Partnerships North America, a position that she held for the last year and a half. Earlier in her career, she worked with TMG – The Marketing Group, where she managed marketing and promotions for Broadway shows in New York and Los Angeles. She earned her BFA in Musical Theatre from the Cincinnati Conservatory of Music. About Logitix Logitix is the preeminent monetization engine and ticketing platform for the live event industry, combining optimized pricing, distribution, and inventory management with real-time insights to help sellers and buyers respond to a rapidly changing market environment. The Logitix vision is to automate the entire ticket life cycle and provide data-driven insights to serve the diverse needs of its clients. The company is backed by ZMC and is privately held. For more information about Logitix, visit Logitix.com or find them on LinkedIn. Contact Details Eric Nemeth +1 602-502-2793 nemeth@ericpr.com Company Website https://logitix.com/

September 06, 2023 07:45 AM Eastern Daylight Time

New Army campaign inspires young Americans to take the first step to “Be All You Can Be”

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Zr1Os51K6G8 On August 21, the U.S. Army unveiled “First Steps,” a new campaign that shows young Americans how they can start their journey to service. The campaign is built on the premise that American youth don’t need to have everything figured out from the beginning to make an impact. Taking a chance is the first step to achieving your goals. The campaign is a continuation of the “Be All You Can Be” brand refresh, which launched in March 2023. The new campaign offers an up-close, personal, and unfiltered look at Soldiers embarking on some of the most powerful experiences in their early Army journeys, including arriving at basic training, receiving their first patch, and hitting their first target from a battle tank. Maj. Sam Winkler is a shining example of where your first steps can take you in the U.S. Army. After immigrating to the United States from Nepal, she took her own first step: enlisting in the Army at 17 years old. Now, as a Soldier and a mom, she has used her passion for family to help lead a first grassroots effort transforming the way the U.S. Army supports parents in the force. Her efforts, in collaboration with other Army parents, led to the development of the Army’s Directive 2022-06: Parenthood, Pregnancy, and Postpartum. Twelve policy changes address key issues like family care planning, fertility treatments, paid parental leave, support in returning to work, and more. On August 30, Maj. Winkler conducted a nationwide media tour discussing the campaign and the limitless opportunities in the Army for youth to find their purpose, explore their passions, build connections, and join a community. Topics Maj. Winkler discussed included: The Army’s new “First Steps” campaign Her path to Army service and the many firsts along the way Her work to improve Army life for parents through the Directive on Parenthood, Pregnancy, and Postpartum The limitless possibilities and benefits available to Army Soldiers and their families To learn more, visit: https://www.goarmy.com/ Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 04, 2023 08:00 AM Eastern Daylight Time

Video

One Media iP Group "continues to move in the right direction"

One Media iP Group PLC

One Media iP Group (AIM:OMIP) chief executive Michael Infante speaks to Proactive after releasing the digital music rights acquirer, publisher and distributor's interim results. He highlights the recent emphasis by the company on developing the TCAT (Technical Copyright Analysis Tool) SaaS platform with a view to spinning it out when the time is right. TCAT, initially a small project within One Media IP, has emerged as a significant player in the fight against piracy. Stewart highlighted that piracy has historically plagued the music industry and has evolved with digital platforms. TCAT's solutions include Tcat Sentinel, which ensures global digital streaming platform coverage, Tcat Protect for identifying and reporting illegal music, and Tcat Insight to ensure accurate songwriter accounting. He also gives his take on how the rest of the business has been performing and what investors can expect from it in the future, saying that One Media "continues to move in what we believe to be a very optimistic and right direction." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 01, 2023 08:07 AM Eastern Daylight Time

Video

QYOU Media Reports Record Q2 FY 2023 Results

QYOU Media

Contact Details Doug Barker +1 437-992-4814 shareholder@qyoutv.com Company Website https://www.valuethemarkets.com

September 01, 2023 06:00 AM Eastern Daylight Time

Video

This K-Culture Fandom App Now Trading On Nasdaq Offers Investors Exposure To Multibillion-Dollar Korean Wave

Benzinga

By Rachael Green, Benzinga A Korean wave has been sweeping the globe for over a decade as first K-pop, then K-drama and now all kinds of Korean entertainment and media continue to draw an increasingly international audience. Today, a single K-pop group, BTS, is responsible for generating over $4.6 billion of South Korea’s GDP. When you add in the rest of the K-pop groups along with the increasingly popular K-dramas, movies and other media, South Korea’s entertainment industry has become a multibillion-dollar global phenomenon. That’s caught the attention of investors looking for ways to gain exposure to this growing global market. For Hanryu Holdings (NASDAQ: HRYU), that’s helped bring in $53 million in capital so far, including nearly $9 million raised during its initial public offering earlier this month. The media-tech company is the creator of FANTOO, an all-in-one social media platform specifically created to give K-culture’s estimated 156 million global fans a place to connect with each other – and buy merchandise, content, concert tickets and more. Here’s how Hanryu is leveraging the economic power of fandom to generate shareholder value. One Fandom App, Multiple Revenue Streams Hanryu reports that since it first launched FANTOO two years ago, the fandom app has grown to 26 million registered users, including 1.5 million active monthly users. Right now, its biggest source of revenue is advertising. The app is an attractive opportunity for brands who want access to this highly engaged audience, and investors interested in the Asian market may want to look deeper. Advertising is far from the app’s only revenue stream. The content creation side that allows users to create and monetize fan art, comics, fan fiction and other content also adds revenue from transaction fees on sales – as does the fan shop where users can buy and sell merchandise on an eBay-style platform. FANTOO also generates money on ticket sales as users unable to attend a concert in-person can pay for a virtual ticket to watch a live stream of the show with fellow fans in the app. Unlike other fandom apps that cater only to a specific fandom, FANTOO is designed to be all-encompassing, creating a space for fans of all forms of K-culture to create clubs, talk to other fans and share their passion. Meanwhile, the app’s reward system lets users earn points for creating content, liking posts, commenting and engaging in other user activity. The unique system helps maintain a consistently high level of engagement from its users, making it an even more attractive advertising opportunity and creating more opportunities to generate cash flow across the app’s other revenue streams. As the app continues to gain users, Hanryu already has big plans to increase its revenue potential, including widening its net to include even more fandoms and launching a metaverse version of FANTOO where users can meet and explore the platform in virtual reality. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 31, 2023 09:15 AM Eastern Daylight Time

Retail Commercial Real Estate Leasing Sets 8-Year Record, See How This Company Is Cashing In On Neighborhood Centers

Benzinga

By Faith Ashmore, Benzinga The commercial real estate industry is grappling with rising inflation and interest rates, as well as other socioeconomic changes that are shaping its trajectory. These challenges have emerged due to a combination of internal and external factors, impacting various segments within the industry. One significant macro problem is the evolving work environment, influenced by the global pandemic and the shift towards remote work. With more employees working from home or adopting hybrid work models, there is a growing concern about the future demand for office space. The industry is grappling with the transformation of retail spaces into experiential and mixed-use developments to remain relevant in the face of e-commerce competition. However, there will always be a need for certain commercial real estate – especially necessity-based real estate. Necessity-based real estate refers to properties that are essential for everyday living and are often in demand regardless of market conditions. This includes sectors such as healthcare facilities, grocery stores, multifamily housing and more. Investing in necessity-based real estate can be a great tool for investors to build resilience and safeguard their investments against market swings. Necessity-based properties have historically shown consistent demand even during economic downturns, making this type of investment suitable for even the current market. The inherent stability of demand in necessity-based real estate contributes to the reduction of risks associated with market fluctuations. By incorporating these essential and reliable property types into their investment strategy, investors can effectively diversify their portfolios. This strategic approach allows investors to mitigate risk, protect their capital and establish long-term financial resilience. Some necessity-based properties are seeing extreme success in today’s market due to unique socio-economic conditions. According to a July 27 article for paid subscribers in The Wall Street Journal titled "The Hottest Real-Estate Play Is in Your Neighborhood," there is a significant opportunity in the commercial real estate sector – particularly in strip malls. Leased occupancy reached an 8-year high of 95.3% in the first quarter of this year, while physical occupancy remained close to its pre-pandemic level at 92.4%. This is because landlords are signing leases faster than retailers are able to move in. Flexible working is contributing to this growth because consumers are spending more time at home and less time in city centers where their offices are located. Additionally, the migration of approximately 2 million people from large cities to suburbs and exurbs has further boosted the demand for strip centers. With office occupancy still at only half of pre-pandemic levels, workday lunches have moved from downtown city centers to restaurants in strip malls closer to people's homes. Additionally, personal care services such as massage, chiropractic, medical laboratory and dental services, which are commonly found in strip retail centers, have experienced strong demand in recent years. First National Realty Partners (FNRP), a renowned necessity-based real estate firm, has established itself as the leader and says it is the inventor of the specific industry. With an impressive track record of success, FNRP has established itself as the go-to investment firm for accredited investors seeking to diversify and navigate the necessity-based market. With over $2 billion in assets under management, FNRP has demonstrated its ability to deliver results for investors. The company’s portfolio boasts an impressive 57 current assets held, showcasing its expertise in identifying and acquiring high-quality properties that align with its investment strategy. Since its inception, FNRP has distributed over $100 million to its valued investors, a testament to generating returns. Its successful growth is evidenced by the acquisition of over 11.5 million square feet of gross leasable area (GLA) across 23 states, solidifying a national presence and extending reach to diverse markets. One key component of FNRP’s strategy is to take advantage of looming headwinds in the real estate market, and it aims to acquire numerous properties at significant discounts over the next few quarters. The company believes that it will be able to leverage its cash and stable positioning to step in and significantly increase its holdings even as competitors sell. As many industry players are looking at selling and drawing down their portfolios, it’s important to understand which firms are prepared. With its focus on recession-resilient real estate, FNRP continues to explore innovative solutions to navigate the current landscape and lay the foundation for future success – accredited investors may want to take note. Learn more about FNRP’s upcoming deals here. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 30, 2023 09:15 AM Eastern Daylight Time

Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible

Benzinga

By Faith Ashmore, Benzinga Colorectal cancer is the third most common cancer worldwid e, and the second most fatal. Although the majority of colorectal cancer cases have historically occurred in individuals aged 50 and older, it is increasingly affecting younger people. Alarming statistics reveal that new cases of colorectal cancer in individuals under the age of 50 have been steadily rising over the past few decades. Colorectal cancer is now the leading cause of cancer death for Americans between the ages of 20 and 59 years old according to the National Cancer Institute. However, younger adults are not routinely screened for colorectal cancer as it is still relatively uncommon in their age group. Determining the exact reasons for this uptick remains a challenge, although many experts believe this trend is being driven by a sedentary lifestyle, obesity, smoking, heavy alcohol use, low-fiber, high-fat diets or diets high in processed meats and other environmental factors. However, even without absolutely clear answers, regular screening is crucial to early detection followed by highly successful treatment of colorectal cancer. The CDC reports that colorectal cancer is the second most fatal cancer in the United States and Europe. However, it is also the most preventable, with early detection leading to survival rates above 90%. Given the rising incidence in young individuals and the majority's lack of regular screenings until later in life, accessible screenings are more important than ever. By providing efficient and convenient methods for early detection, healthcare professionals can make significant progress in combating colorectal cancer and ultimately save countless lives. Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The test is the first DNA-based screening test for colorectal cancer in Europe. ColoAlert has been recommended by the U.S. Preventive Services Task Force – stool DNA tests, such as ColoAlert, should be conducted once every three years, starting at age 45. Every year, 16.6 million colonoscopies are performed in the U.S. alone, and yet one-third of U.S. residents aged 50-75 have never been screened for colon cancer. Many times, fear of a colonoscopy contributes to populations avoiding the screening; ColoAlert is a non-invasive solution to the long-standing apprehension. Simply put, this innovative screening tool is not limited to younger ages. In fact, ColoAlert may have an annual market opportunity in excess of $4.0 Billion in the U.S. for testing populations aged 50 and above every three years. ColoAlert's unique genetic profiles allow for tailored treatment for each individual patient, leading to better health outcomes for patients with colorectal cancer. This revolutionary product is a major stride in combating colorectal cancer and has the potential to save countless lives. Mainz Biomed is quickly emerging as a strong contender in the diagnostic industry, putting renowned companies like Exact Sciences (NASDAQ: EXAS) and Geneoscopy Inc. on notice. While both Exact Sciences and Geneoscopy utilize DNA and RNA biomarkers respectively, Mainz Biomed is breaking new ground by revolutionizing the field with its cutting-edge evaluation of groundbreaking patent-pending mRNA biomarkers. This is evident by the company's ColoAlert® recent success in the market. The revenues generated by ColoAlert® in the first half of 2023 surged by an impressive 108% when compared to the same period in 2022. This remarkable growth further solidifies Mainz Biomed's position in the industry and showcases its ability to develop groundbreaking products that meet the needs of healthcare professionals and patients alike. With its pioneering approach and revenue growth over H1 this year, Mainz Biomed seems poised to disrupt the market and establish itself as a trusted and innovative provider of molecular genetic diagnostic solutions. Their commitment to pushing the boundaries of diagnostic technology and growth trajectory seems to be making them a force to be reckoned with in the industry, setting them apart from their competitors. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 30, 2023 09:15 AM Eastern Daylight Time

1 ... 82 83 84 85 86 ... 337